Hemophilia Explained: Causes, Symptoms

(Note: For PDF File Swipe To The End Of Article)

Introduction

Hemophilia is a rare inherited bleeding disorder in which the blood does not clot properly because certain clotting factors are missing or present at insufficient levels. These clotting factors are proteins that help stop bleeding after an injury. When one of these proteins is deficient, bleeding may continue for longer than expected, and bleeding can sometimes occur inside the body without an obvious injury.

Hemophilia is most commonly associated with deficiencies of clotting factor VIII or clotting factor IX. A deficiency of factor VIII causes hemophilia A, while a deficiency of factor IX causes hemophilia B. Although both conditions produce similar symptoms, they involve different clotting proteins and may require different treatment products.

Hemophilia can affect people throughout their lives. Some individuals are diagnosed during infancy or early childhood, while others are not diagnosed until they experience unusual bleeding after surgery, dental procedures, or an injury. The severity of the condition varies considerably. People with severe hemophilia may experience spontaneous bleeding into joints and muscles, whereas those with mild disease may bleed excessively only after significant trauma or medical procedures.

Historically, hemophilia was associated with serious complications, disability, and a reduced life expectancy. Advances in clotting-factor replacement, preventive treatment, laboratory diagnosis, and newer therapies have substantially improved outcomes. Many people with hemophilia can now attend school, work, exercise, and participate in family and social life with appropriate medical care.

However, hemophilia remains a condition that requires careful monitoring. Bleeding into the brain, throat, abdominal organs, or other critical areas can become life-threatening. Repeated bleeding into joints may cause permanent damage if not prevented or treated promptly.

This comprehensive article explains hemophilia in detail, including its definition, types, causes, inheritance, symptoms, severity, diagnosis, treatment, complications, prevention strategies, and long-term management.

1. What Is Hemophilia?

Hemophilia is a congenital or inherited bleeding disorder characterized by reduced activity of specific blood-clotting factors.

Under normal circumstances, the body controls bleeding through a process called hemostasis. When a blood vessel is damaged, several mechanisms work together to limit blood loss and repair the injury.

First, the injured blood vessel constricts. Platelets then attach to the damaged area and form an initial platelet plug. Clotting proteins activate one another through a series of biochemical reactions, producing thrombin, which converts fibrinogen into fibrin.

Fibrin forms a stabilizing network around the platelet plug, helping create a stronger blood clot.

In hemophilia, the clotting process is impaired because factor VIII or factor IX activity is insufficient. The initial platelet plug may form, but the clot may not develop the stability needed for effective bleeding control.

As a result, a person with hemophilia may experience:

• Prolonged bleeding after injuries.
• Excessive bleeding after surgery or dental extraction.
• Recurrent bleeding into joints.
• Bleeding into muscles and soft tissues.
• Deep bruising or large hematomas.
• Internal bleeding without an obvious external wound.

Importantly, hemophilia is not usually caused by a low platelet count. Platelets may be normal in number and function, but the clotting-factor deficiency prevents the formation of a sufficiently stable clot.

Hemophilia also does not generally mean that blood is thinner than normal. Instead, the blood's ability to form and stabilize a clot is impaired.

2. How Does Normal Blood Clotting Work?

Understanding normal blood clotting helps explain why hemophilia causes bleeding.

The body's clotting system consists of blood vessels, platelets, clotting factors, and regulatory proteins that prevent uncontrolled clot formation.

A. Blood vessel injury

When a blood vessel is damaged, the vessel constricts to reduce blood flow through the injured area.

The damaged surface exposes structures that attract platelets and activate the clotting system.

B. Platelet plug formation

Platelets are small cell fragments circulating in the bloodstream.

They adhere to the damaged vessel wall, become activated, and release chemical signals that attract additional platelets.

These platelets aggregate to form a temporary plug.

C. Activation of clotting factors

Clotting factors are proteins that participate in a coordinated series of reactions.

Factor VIII acts as a cofactor for activated factor IX. Together, they help activate factor X, which contributes to the production of thrombin.

Thrombin then converts fibrinogen into fibrin.

D. Formation of a stable clot

Fibrin strengthens the platelet plug and helps stabilize the clot.

This is essential because an initial platelet plug alone may not withstand normal blood flow and pressure.

E. Tissue repair

Once bleeding is controlled, the body begins repairing the damaged tissue. Eventually, the clot is gradually broken down as healing progresses.

In hemophilia A, insufficient factor VIII activity disrupts the reaction involving factor IX. In hemophilia B, insufficient factor IX activity interferes with the same stage of the clotting process.

Both deficiencies reduce the body's ability to produce enough thrombin and form a stable fibrin clot.

3. What Are the Main Types of Hemophilia?

The two major forms are hemophilia A and hemophilia B.

A third condition, sometimes called hemophilia C, is a factor XI deficiency. However, it differs from classic hemophilia A and B in its inheritance pattern, bleeding characteristics, and clinical management.

A. Hemophilia A

Hemophilia A results from a deficiency or dysfunction of clotting factor VIII.

It is the most common form of hemophilia.

Hemophilia A may be inherited through changes in the F8 gene, which provides instructions for making factor VIII.

The condition can range from mild to severe depending on the remaining factor VIII activity.

People with severe hemophilia A may develop spontaneous joint and muscle bleeding. Individuals with mild hemophilia A may remain undiagnosed until a surgical procedure, dental extraction, or significant injury exposes the bleeding tendency.

B. Hemophilia B

Hemophilia B results from a deficiency or dysfunction of clotting factor IX.

It is sometimes called Christmas disease, a historical name derived from an early described patient, not from the holiday.

Hemophilia B is associated with changes in the F9 gene.

Its symptoms can closely resemble those of hemophilia A. The severity depends on the amount of functional factor IX available.

Although hemophilia A is more common, hemophilia B can also cause serious spontaneous bleeding, joint damage, and life-threatening internal hemorrhage.

C. Factor XI deficiency

Factor XI deficiency is sometimes referred to as hemophilia C.

Unlike hemophilia A and B, factor XI deficiency is not typically inherited through the same X-linked pattern. It commonly follows an autosomal inheritance pattern and affects males and females.

Its bleeding pattern is often different. Some individuals have little spontaneous bleeding but experience excessive bleeding after surgery, dental procedures, or trauma, particularly in tissues with high fibrinolytic activity, such as the mouth and urinary tract.

Factor XI deficiency should therefore be distinguished from classic hemophilia A and B.

4. What Causes Hemophilia?

Hemophilia is most often caused by a genetic change that affects the production or function of a clotting factor.

In hemophilia A, the change usually affects the F8 gene. In hemophilia B, it affects the F9 gene.

These genes provide instructions for producing factor VIII and factor IX, respectively.

Genetic changes can include deletions, insertions, substitutions, or other alterations that interfere with protein production or function.

Depending on the specific genetic change, a person may produce very little clotting factor, no functional factor, or a protein that works less effectively than normal.

A. Inherited genetic changes

Many cases occur because a child inherits a disease-causing genetic variant from a parent who carries it.

However, not every person with hemophilia has a known family history.

B. New genetic changes

A genetic variant may arise for the first time in an egg cell, sperm cell, or early embryo.

Such a change is called a de novo variant.

This explains why hemophilia can occur in a family even when no previous relatives are known to have had the condition.

C. Acquired hemophilia

Rarely, a person develops hemophilia-like bleeding because the immune system produces antibodies that interfere with a clotting factor.

This condition is called acquired hemophilia, most commonly acquired hemophilia A, because the antibodies target factor VIII.

Acquired hemophilia is different from the inherited forms. It often affects adults who have no previous personal or family history of a bleeding disorder.

It may occur in association with autoimmune diseases, certain cancers, pregnancy or the period after childbirth, or certain medications, although in many cases no clear cause is identified.

Acquired hemophilia can cause severe bleeding into the skin, muscles, soft tissues, and other areas. It requires urgent specialist assessment and treatment.

5. How Is Hemophilia Inherited?

Hemophilia A and hemophilia B are usually inherited in an X-linked pattern.

The genes involved are located on the X chromosome.

Typically, females have two X chromosomes, while males have one X chromosome and one Y chromosome. These chromosome patterns are common biological arrangements, although variations exist.

A person with one X chromosome who inherits a disease-causing variant in F8 or F9 generally develops hemophilia because there is no second X chromosome carrying another copy of the gene.

A person with two X chromosomes may inherit one affected copy and one unaffected copy. Such individuals are often described as carriers, but they may also have reduced clotting-factor levels and clinically significant bleeding.

A. When the mother is a carrier

If a mother carries a disease-causing variant in F8 or F9 and the father does not have hemophilia, each pregnancy has:

• A 50% chance of passing the affected X chromosome to the child.
• A 50% chance of passing the unaffected X chromosome to the child.

If the child inherits the affected X chromosome, a son will generally have hemophilia, while a daughter will generally be a carrier. However, females who inherit the variant may also have hemophilia or significant bleeding symptoms.

These probabilities apply independently to each pregnancy.

B. When the father has hemophilia

A father passes his X chromosome to all his daughters and his Y chromosome to all his sons.

Therefore, if a father has an X-linked form of hemophilia and the mother does not carry the relevant variant:

• All daughters inherit the father's affected X chromosome.
• None of his sons inherit that X chromosome from him.

Daughters may be carriers and may have reduced factor levels or bleeding symptoms.

C. Can females have hemophilia?

Yes.

Although hemophilia A and B are more frequently diagnosed in males, females can have hemophilia.

This may occur because of particular genetic circumstances, including inheritance of disease-causing variants affecting both X chromosomes, certain chromosome patterns, or unfavorable X-chromosome inactivation.

Some females have factor levels low enough to meet criteria for mild, moderate, or severe hemophilia.

Others have factor levels within the laboratory reference range but still experience abnormal bleeding.

For this reason, a female who experiences heavy menstrual bleeding, excessive bleeding after childbirth, frequent nosebleeds, or prolonged bleeding after procedures should not have a bleeding disorder dismissed solely because she is female.

D. Genetic counseling

Genetic counseling can help families understand inheritance, testing options, reproductive choices, and the implications of a genetic diagnosis.

Families may consider testing for known familial variants, particularly when planning pregnancy or evaluating relatives who may be affected.

Genetic counseling should be individualized and nonjudgmental, recognizing that people have different preferences and circumstances.

6. Classification of Hemophilia by Severity

Hemophilia is commonly classified according to the percentage of normal clotting-factor activity measured in the blood.

The classification generally applies to factor VIII activity in hemophilia A and factor IX activity in hemophilia B.

Severity	Clotting-factor activity	Typical bleeding pattern
Severe	Less than 1%	Spontaneous bleeding and frequent joint or muscle bleeds
Moderate	1%–5%	Bleeding after minor trauma and occasional spontaneous bleeds
Mild	Greater than 5% and less than 40%	Excessive bleeding mainly after surgery, dental work, or significant injury

These categories are widely used, but the actual bleeding pattern can vary between individuals.

A. Severe hemophilia

People with severe hemophilia have very low levels of factor VIII or factor IX activity.

Bleeding may occur without a clear injury, particularly into joints and muscles.

Without effective preventive treatment, repeated bleeding can lead to chronic pain, joint deformity, reduced mobility, and disability.

Severe hemophilia is often diagnosed during infancy or early childhood, especially when bruising, bleeding after injections, or prolonged bleeding following minor injuries becomes apparent.

B. Moderate hemophilia

People with moderate hemophilia have higher factor activity than those with severe disease but still have a substantial bleeding risk.

They may bleed excessively after relatively minor injuries and occasionally experience spontaneous bleeding.

Some individuals are diagnosed during childhood, while others may be diagnosed later depending on their activity level and exposure to injuries or medical procedures.

C. Mild hemophilia

Mild hemophilia may remain unnoticed for many years.

A person may not have frequent spontaneous bleeding but may experience prolonged bleeding following surgery, tooth extraction, childbirth, or significant trauma.

Because symptoms can be subtle, mild hemophilia may be diagnosed only after an unexpected bleeding episode.

Mild disease should not be considered harmless. Major surgery, serious injury, or bleeding in a critical location can still lead to severe complications.

7. Signs and Symptoms of Hemophilia

The symptoms of hemophilia depend on the severity of the clotting-factor deficiency, the location of bleeding, and the individual's treatment history.

The most characteristic feature is prolonged or excessive bleeding.

A. Easy bruising

People with hemophilia may develop large or deep bruises after relatively minor impacts.

Bruises occur when blood leaks from small blood vessels into surrounding tissues.

Children may develop bruises as they begin crawling, walking, and exploring their surroundings. Frequent unexplained bruising, especially in combination with other bleeding symptoms, should be assessed by a healthcare professional.

B. Prolonged bleeding after injury

Cuts, scrapes, and other injuries may bleed for longer than expected.

The initial bleeding may appear controlled, only to restart later if the clot is not sufficiently stable.

C. Nosebleeds

Some people experience recurrent nosebleeds.

Nosebleeds are common in the general population and do not automatically indicate hemophilia. However, repeated or unusually prolonged episodes may warrant evaluation, especially when accompanied by other bleeding symptoms.

D. Bleeding from the mouth and gums

Bleeding may occur after dental extraction, oral injury, or certain dental procedures.

Gum bleeding can also result from gingivitis, poor oral hygiene, or other conditions, so it is not specific to hemophilia.

E. Joint bleeding

Bleeding into joints is called hemarthrosis.

It is one of the most characteristic complications of severe hemophilia.

Commonly affected joints include:

• Knees.
• Ankles.
• Elbows.

A joint bleed may produce pain, swelling, warmth, tightness, and difficulty moving the affected joint.

Repeated joint bleeding can damage cartilage and surrounding tissues, eventually causing chronic joint disease.

F. Muscle bleeding

Blood can accumulate within muscles, producing pain, swelling, tenderness, and reduced movement.

Deep muscle bleeding may compress nearby nerves or blood vessels. Bleeding in certain muscle compartments can become a medical emergency.

G. Excessive bleeding after medical procedures

People with hemophilia may experience excessive bleeding after:

• Dental extraction.
• Surgery.
• Certain injections.
• Significant injuries.
• Some invasive diagnostic procedures.

Planned procedures require advance coordination with the hemophilia treatment team.

H. Blood in urine

Hematuria, or blood in the urine, may occur in people with hemophilia.

However, urinary bleeding has many other causes, including infection, kidney stones, and urinary tract disorders. It requires appropriate assessment rather than being automatically attributed to hemophilia.

I. Gastrointestinal bleeding

Bleeding from the gastrointestinal tract may produce vomiting of blood, black tarry stools, or red blood in the stool.

These symptoms require urgent medical evaluation.

J. Intracranial bleeding

Bleeding inside the skull is one of the most dangerous complications.

Symptoms may include severe headache, vomiting, drowsiness, confusion, weakness, seizures, or loss of consciousness.

Head injury in a person with hemophilia requires urgent assessment, even when external signs appear minor.

8. Hemarthrosis: Bleeding Into the Joints

Hemarthrosis deserves particular attention because recurrent joint bleeding is a major cause of long-term disability in untreated or inadequately treated hemophilia.

How does joint bleeding develop?

Blood enters the joint space and irritates the synovial membrane, which lines the inside of the joint.

The blood and its breakdown products can trigger inflammation and changes in the synovial tissue.

Repeated episodes may lead to synovial thickening, increased blood-vessel formation, cartilage damage, and erosion of bone.

This progressive process is sometimes called hemophilic arthropathy.

Early signs of a joint bleed

Early symptoms may include:

• A sensation of fullness or tightness.
• Tingling or an unusual feeling in the joint.
• Mild discomfort.
• Reduced range of motion.
• Increasing warmth or swelling.

As bleeding progresses, pain and movement limitation may become more severe.

Why is early treatment important?

Prompt treatment can reduce the duration of bleeding and help limit damage.

A person with hemophilia should follow their individualized bleeding-management plan and contact their treatment team promptly when a joint bleed is suspected.

Treatment should not be delayed while waiting for severe swelling or intense pain to develop.

Can joint damage be prevented?

Preventive treatment can substantially reduce bleeding episodes and help preserve joint health.

Regular physical activity, appropriate muscle strengthening, physiotherapy, and avoidance of repeated joint trauma also support long-term function.

However, exercise recommendations should be tailored to the individual's factor level, treatment regimen, joint condition, and activity.

9. Hemophilia in Infants and Children

Hemophilia may be suspected during infancy, especially when a child develops unusual bleeding after an injury or procedure.

Some children are diagnosed before birth or shortly afterward because a family history is known.

Others are diagnosed when symptoms appear during normal childhood activities.

Early warning signs

Possible signs in infants and children include:

• Excessive bruising.
• Prolonged bleeding after a blood sample is taken.
• Large bruises during crawling or walking.
• Swelling or pain around a joint.
• Bleeding after surgery or circumcision.
• Unusual bleeding following minor trauma.
• Head swelling or neurological symptoms after an injury.

These signs are not unique to hemophilia. Other inherited or acquired bleeding disorders can produce similar symptoms.

Why can diagnosis be delayed?

Mild hemophilia may not become obvious until a child undergoes surgery, experiences a significant injury, or begins activities that increase the risk of bleeding.

A child with no known family history may also be diagnosed later because the condition was not initially suspected.

School and daily activities

Children with hemophilia can generally attend school and participate in many normal childhood activities with appropriate care.

Parents, teachers, school nurses, and other caregivers should know whom to contact if bleeding occurs and understand the child's individualized emergency plan.

The aim is to support normal development while reducing preventable injuries.

10. Hemophilia in Females and Women

Females with hemophilia or carrier status may experience clinically important bleeding.

The severity depends partly on clotting-factor activity, genetic circumstances, and other individual factors.

A. Heavy menstrual bleeding

Heavy menstrual bleeding can cause anemia, fatigue, reduced concentration, and disruption of everyday activities.

Symptoms may include prolonged periods, passing large clots, or needing to change menstrual products unusually frequently.

Heavy periods are common for many reasons, but persistent symptoms should prompt appropriate evaluation for anemia and bleeding disorders.

B. Pregnancy

Pregnancy requires coordinated care because clotting-factor levels may change during gestation.

Factor VIII often rises during pregnancy, whereas factor IX generally does not show the same physiological increase. Individual responses vary.

A pregnant woman with hemophilia or carrier status may require factor measurements, obstetric planning, and specialist assessment before delivery.

C. Delivery and postpartum bleeding

The delivery plan should consider the mother's factor levels, bleeding history, and the baby's potential risk of hemophilia.

Postpartum bleeding may occur because factor levels can fall after childbirth, particularly in women whose factor VIII increased during pregnancy.

A coordinated plan may include appropriate clotting-factor treatment, monitoring, and precautions for invasive procedures.

D. Genetic testing and family planning

Women from families affected by hemophilia may benefit from genetic counseling and factor testing.

Knowing carrier status can guide personal medical care, reproductive decisions, pregnancy planning, and assessment of children.

11. Acquired Hemophilia: When Hemophilia Develops Later in Life

Acquired hemophilia is a rare but potentially serious bleeding disorder caused by antibodies that interfere with clotting factor activity.

The most commonly affected factor is factor VIII.

Unlike inherited hemophilia, acquired hemophilia can appear in someone who has never experienced abnormal bleeding before.

Who can develop acquired hemophilia?

It can occur in adults of different ages.

Some cases are associated with autoimmune disease, cancer, pregnancy, or the postpartum period. However, many cases are considered idiopathic, meaning that no clear underlying cause is identified.

Symptoms

Acquired hemophilia often causes bleeding into the skin, muscles, and soft tissues.

Large bruises may appear without significant trauma. Bleeding may also occur after medical procedures or in internal organs.

Joint bleeding, which is characteristic of inherited severe hemophilia, is less prominent in acquired hemophilia.

Diagnosis

Testing may reveal a prolonged activated partial thromboplastin time (aPTT), with further investigations identifying a factor VIII inhibitor.

A mixing study, factor assays, and inhibitor testing may be needed.

The interpretation can be complex, so specialist laboratory and hematology input is important.

Treatment

Treatment generally has two goals:

1. Control active bleeding.
2. Suppress the antibody responsible for the factor deficiency.

Specialists may use bypassing agents, recombinant porcine factor VIII in appropriate settings, immunosuppressive treatment, or other therapies based on the patient's circumstances.

Because acquired hemophilia can cause serious internal bleeding, suspected cases require urgent specialist management.

12. How Is Hemophilia Diagnosed?

Diagnosis involves clinical assessment, coagulation testing, clotting-factor assays, and sometimes genetic testing.

The exact approach depends on the patient's symptoms, age, family history, and treatment history.

A. Medical history

The clinician may ask about:

• Unusual bruising.
• Prolonged bleeding after injuries.
• Bleeding after surgery or dental extraction.
• Recurrent joint or muscle bleeding.
• Family history of hemophilia.
• Heavy menstrual bleeding.
• Previous blood transfusions or clotting-factor treatment.
• Medications that affect clotting.

A detailed family history can provide important clues, but the absence of affected relatives does not exclude hemophilia.

B. Physical examination

The examination may assess bruises, joint swelling, muscle tenderness, range of motion, and signs of internal bleeding.

If serious bleeding is suspected, emergency assessment and treatment take priority over completing every diagnostic test.

C. Complete blood count

A complete blood count measures hemoglobin, white blood cells, and platelets.

The platelet count is generally normal in hemophilia A and B.

Hemoglobin may decrease if substantial or repeated bleeding has occurred.

A normal CBC does not exclude hemophilia.

D. Prothrombin time

Prothrombin time, or PT, evaluates part of the blood-clotting system.

PT is usually normal in classic hemophilia A and B because the primary defect affects a different portion of the clotting pathway.

E. Activated partial thromboplastin time

Activated partial thromboplastin time, or aPTT, evaluates another part of the clotting system.

In moderate or severe hemophilia A or B, aPTT is often prolonged.

However, aPTT may be normal in some people with mild hemophilia, depending on the factor level and the sensitivity of the laboratory method.

A normal aPTT therefore does not reliably exclude mild hemophilia.

F. Factor VIII and factor IX assays

Specific clotting-factor assays measure factor VIII and factor IX activity.

These tests help establish the diagnosis and determine severity.

Factor assays are essential because PT and aPTT alone cannot reliably distinguish hemophilia A from hemophilia B.

G. Genetic testing

Genetic testing can identify the disease-causing variant in F8 or F9.

It can help confirm the diagnosis, identify carriers, support family counseling, and sometimes inform treatment decisions.

Not every patient requires genetic testing to establish a clinical diagnosis, but it can be particularly useful in family planning and evaluation of relatives.

H. Testing for inhibitors

Some patients develop antibodies that neutralize infused clotting factors.

These are called inhibitors.

Inhibitor testing may be performed when factor treatment does not produce the expected response, when bleeding is difficult to control, or as part of recommended monitoring.

The Bethesda assay and related methods can help quantify inhibitors.

I. Prenatal and newborn diagnosis

When a family history or known genetic variant creates a substantial risk, prenatal genetic counseling and testing may be considered.

After birth, diagnosis can be supported by factor assays and genetic testing when appropriate.

Factor VIII levels are relatively high at birth compared with later childhood, while factor IX levels may be lower in newborns, particularly premature infants. This difference can influence interpretation and the timing of repeat testing.

A specialist should guide testing when hemophilia is suspected in a newborn.

13. Differential Diagnosis: Conditions That Resemble Hemophilia

Not every person with prolonged bleeding has hemophilia.

Several other disorders can produce similar symptoms.

A. Von Willebrand disease

Von Willebrand disease is a common inherited bleeding disorder involving von Willebrand factor, a protein that helps platelets adhere to injured blood vessels and also stabilizes factor VIII.

Symptoms often include nosebleeds, easy bruising, heavy menstrual bleeding, and prolonged bleeding after dental procedures.

Its diagnostic tests differ from those used for classic hemophilia.

B. Platelet disorders

Low platelet counts or impaired platelet function can cause mucosal bleeding, bruising, and prolonged bleeding from small cuts.

The platelet count and additional platelet-function studies help distinguish these conditions from hemophilia.

C. Vitamin K deficiency

Vitamin K is needed for the production of several clotting factors.

Severe deficiency can impair clotting and may prolong PT, depending on the circumstances.

D. Liver disease

The liver produces many clotting proteins.

Significant liver dysfunction can alter multiple coagulation tests and cause bleeding, although the overall clotting changes in liver disease are complex.

E. Other clotting-factor deficiencies

Deficiencies of factors other than VIII and IX can produce prolonged bleeding.

Specific factor assays help establish which factor is affected.

F. Acquired coagulation inhibitors

Autoantibodies against clotting factors can cause an acquired bleeding disorder.

These conditions may resemble inherited hemophilia but require a different diagnostic and treatment approach.

14. Treatment of Hemophilia: An Overview

Treatment depends on the type and severity of hemophilia, bleeding history, inhibitor status, availability of therapies, and individual needs.

The major goals are to:

• Prevent bleeding episodes.
• Treat bleeding promptly.
• Protect joints and muscles.
• Prevent life-threatening complications.
• Support normal growth, mobility, education, and employment.
• Improve quality of life.

Treatment should be planned with a hematologist or specialized hemophilia treatment center whenever possible.

The main approaches include clotting-factor replacement, non-factor preventive therapies, selected medicines that increase endogenous factor activity, gene therapy for eligible patients, and supportive care.

15. Clotting-Factor Replacement Therapy

Clotting-factor replacement is a foundational treatment for hemophilia A and B.

The treatment supplies the deficient clotting factor so the body can form a more stable clot.

A. Factor VIII replacement

In hemophilia A, factor VIII concentrate can be administered intravenously.

Products include recombinant factor VIII and certain plasma-derived factor VIII preparations.

The product, dose, and treatment frequency depend on the severity of bleeding, the patient's factor level, body weight, pharmacokinetics, and treatment plan.

B. Factor IX replacement

Hemophilia B is treated with factor IX replacement.

Recombinant factor IX concentrates are widely used, and extended-half-life products can reduce the frequency of preventive infusions for some patients.

C. Treatment of active bleeding

When bleeding occurs, factor replacement may be used to raise the factor level sufficiently to control the episode.

The required target depends on the location and severity of bleeding.

A minor joint bleed and a suspected intracranial hemorrhage require very different levels of urgency and treatment intensity.

D. Preventive factor replacement

Prophylaxis means administering treatment regularly to prevent bleeding before it occurs.

For severe hemophilia, prophylaxis can substantially reduce spontaneous bleeding and protect joint health.

Treatment schedules vary. Some products require relatively frequent infusions, while others remain active longer.

E. Advantages and limitations

Factor replacement is effective and has transformed hemophilia care.

However, treatment can be expensive, requires access to suitable products, and may involve repeated intravenous infusions.

Some patients develop inhibitors that reduce the effectiveness of factor replacement. In such cases, alternative treatment strategies may be necessary.

16. Non-Factor Therapy for Hemophilia A

Some treatments reduce bleeding without directly replacing the missing clotting factor.

Emicizumab is an example of a non-factor preventive therapy used for hemophilia A.

It is a laboratory-designed antibody that brings activated factor IX and factor X into closer proximity, helping reproduce part of the function normally supported by factor VIII.

How is emicizumab administered?

Emicizumab is given by subcutaneous injection.

Depending on the prescribed regimen, maintenance doses are administered at regular intervals that may be weekly, every two weeks, or every four weeks.

The exact schedule must follow the clinician's instructions and the product-specific guidance.

Who may receive emicizumab?

It can be used for bleeding prevention in eligible people with hemophilia A, including those with factor VIII inhibitors.

Its role depends on the patient's age, treatment history, local approval, clinical circumstances, and access.

Does emicizumab cure hemophilia?

No. It helps prevent bleeding but does not correct the underlying F8 gene variant or restore natural factor VIII production.

Patients still need an individualized plan for breakthrough bleeding, surgery, dental procedures, and emergencies.

Important safety consideration

Certain coagulation tests, especially the aPTT, become misleading during emicizumab treatment.

Some factor VIII activity assays based on aPTT may also produce inaccurate results.

The laboratory and treating team must know that the patient is receiving emicizumab so appropriate testing methods can be used.

In addition, some combinations of treatments used to control bleeding in patients with inhibitors may increase the risk of serious complications. These decisions require specialist guidance.

17. Desmopressin in Mild Hemophilia A

Desmopressin, also called DDAVP, can increase the release of stored factor VIII and von Willebrand factor in selected patients.

It may be useful for some people with mild hemophilia A, particularly before certain procedures or for selected bleeding episodes.

How does it work?

Desmopressin stimulates the release of stored von Willebrand factor and factor VIII from the body's tissues, temporarily increasing their levels in the bloodstream.

Is it suitable for everyone?

No.

The response varies, and a test dose may be needed to determine whether an individual achieves a sufficient factor VIII increase.

It is not effective for hemophilia B because it does not raise factor IX activity in a clinically useful way.

It is also generally insufficient for severe hemophilia A.

Potential adverse effects

Desmopressin can cause fluid retention and low blood sodium, particularly if fluid intake is not appropriately managed.

It should be used according to a clinician's instructions, with attention to fluid restrictions and other precautions.

18. Antifibrinolytic Medicines

Antifibrinolytic medicines, including tranexamic acid, help prevent the breakdown of blood clots.

They may be particularly useful for bleeding involving the mouth, nose, and certain dental procedures.

They are often used as part of a broader treatment plan rather than as a substitute for clotting-factor replacement when a significant factor deficiency requires replacement.

The appropriateness of these medicines depends on the type and location of bleeding, kidney function, other medical conditions, and the clinician's assessment.

They are not suitable for every bleeding situation. For example, blood in the urine requires careful medical assessment before antifibrinolytic treatment because clots may obstruct urinary flow in some circumstances.

19. Treatment of Hemophilia With Inhibitors

An inhibitor is an antibody that interferes with the activity of a clotting factor administered as treatment.

Inhibitors are a significant complication, particularly in severe hemophilia A, although they can also occur in hemophilia B.

Why do inhibitors develop?

The immune system may recognize infused factor VIII or factor IX as foreign and produce antibodies that reduce its effectiveness.

Risk depends on genetic and treatment-related factors, but inhibitors cannot always be predicted.

How are inhibitors detected?

Doctors may suspect an inhibitor when factor replacement does not produce the expected clinical response.

Specific laboratory tests, including inhibitor assays, can confirm the presence and estimate the level of the inhibitor.

Treatment options

Depending on the type of hemophilia and the inhibitor, treatment may include:

• Bypassing agents that support clot formation through alternative pathways.
• Non-factor preventive treatment, such as emicizumab for eligible patients with hemophilia A.
• Immune tolerance induction, in which repeated factor exposure is used to try to eliminate the inhibitor.
• Other specialist-directed therapies.

Immune tolerance induction is an established strategy for selected patients, particularly those with factor VIII inhibitors, but it can require prolonged treatment and is not successful in every case.

Patients with inhibitors need an individualized plan because the optimal therapy depends on the specific inhibitor, bleeding severity, and preventive treatment already being used.